Results 191 to 200 of about 5,293,476 (246)

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma. [PDF]

ESMO Open
Heurtier V, Marret G, Lamy C, Hamza A, Diallo MH, Ahmanache L, Vacher S, Schnitzler A, Courtois L, Jeannot E, Klijanienko J, El Beaino Z, Gal J, Ledru M, Martinat C, Martin J, Choussy O, Dubray-Vautrin A, Lesnik M, Ghanem W, Taouachi R, Badois N, Nhy C, Borcoman E, Flavius J, Kadi A, Berger F, Servant N, Kamal M, Bièche I, Le Tourneau C.   +30 more
europepmc   +1 more source

Lower Eyelid Cutaneous Squamous Cell Carcinoma: Oncologic Resection and Reconstruction With a Mustardé Rotation Flap. [PDF]

Cureus
Domínguez Gamboa LS, Herrera Sandoval AI, Duran García LE, García Castelán G, Colli Mas BM, Menjivar Rivera OM.   +5 more
europepmc   +1 more source

Correction to “Intratumoral Fusobacterium nucleatum Drives Cancer‐Associated Fibroblasts Enrichment and Immune Exclusion in Esophageal Squamous Cell Carcinoma”

Annals of Gastroenterological Surgery, EarlyView.
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Correction to "HK2/VDAC1 Axis Regulates Malignant Progression of Esophageal Squamous Cell Carcinoma". [PDF]

Cancer Med
europepmc   +1 more source

Correction: Curcumin inhibits glycolysis via EP300 in oral squamous cell carcinoma. [PDF]

Sci Rep
Tang W, Zhang C, Han L, Fu H, Mao Z, Zhang Y, Liu Y, Li L, Yu J.   +8 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

The Clinicodemographic Features of Oral Squamous Cell Carcinoma: A Single-Centre Retrospective Study. [PDF]

Int J Dent
Jain N, Keshwar S, Raut T, Sarraf DP, Agrawal N.   +4 more
europepmc   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source